Duke 100510: Phase II study of Dose-Reduced Consolidation Radiation Therapy in Patients
Evaluate whether a reduction in radiation dose and field size will maintain a high
rate of local control while minimizing the risk of acute and late toxicity .
Basic Study Information
Purpose:Location: University of Rochester James P. Wilmot Cancer Institute
This phase II study will evaluate whether a reduction in radiation dose and field
size will maintain a high rate of local control while minimizing the risk of acute
and late toxicity .
Hypothesis: The radiation dose and treatment volume can be safely reduced from 30
Gy to 20 Gy while maintaining high rates of local control in patients who had a negative
PET-CT scan following rituximab - containing chemotherapy.
Study Reference #: RLYM19037
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search